Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura

Trial Profile

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fostamatinib (Primary)
  • Indications Idiopathic thrombocytopenic purpura
  • Focus Therapeutic Use
  • Acronyms FIT; FIT3; HAEM 3426
  • Sponsors Rigel Pharmaceuticals
  • Most Recent Events

    • 13 Jun 2019 According to a Rigel Pharmaceuticals media release, data from the study will be presented at the 24 Congress of the European Hematology Association (EHA) 2019.
    • 04 Dec 2018 Results of post-hoc analysis (n=123; data cutoff 8 March 2018) evaluating safety and efficacy of Fostamatinib in adult patients with Immune Thrombocytopenia presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 01 Nov 2018 According to a Rigel Pharmaceuticals media release, data from this trial will be presented at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition to be held December 1-4, 2018, in San Diego, CA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top